MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
Warren, NJ (November 26, 2008) – MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that A. Mark Schobel, president and CEO, and Keith J. Kendall, executive vice president and CFO, are scheduled to present at the 20th Annual Piper Jaffray Health Care Conference to be held December 2-3, 2008 at the New York Palace in New York City.
Event: 20th Annual Piper Jaffray Health Care Conference
Date: Wednesday, December 3, 2008
Time: 9:50 a.m. ET
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver prescription drugs in quick dissolving films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company is a leader in thin film drug delivery and has a strong intellectual property position, a portfolio of commercialized OTC drug products, and a pipeline of prescription formulations utilizing its PharmFilm® technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture prescription and OTC drug products for near, mid and long-term revenues.
The Company’s commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company’s existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and ODTs.
Media / Investors:
The Ruth Group
Jason Rando (media)
Stephanie Carrington/ Sara Ephraim (investors)
Chief Financial Officer